VOLITIONRX LTD — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
VolitionRx filed an 8-K on 2026-08-24 disclosing an unregistered sale of equity securities (Item 3.02) as of 2026-08-19. The filing provides no specific details: no counterparty name, dollar amount, share count, price per share, or use of proceeds are stated in the accessible text. This represents a material disclosure gap for a $72.9M market-cap company.
Why this rating
Without specifics (amount, shares, pricing), cannot assess materiality. Unregistered sales are routine for biotech; filing itself is standard Item 3.02 disclosure—likely routine unless hidden details are material.
Extracted items
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.